JGC
GLUE icon

J. Goldman & Co’s Monte Rosa Therapeutics GLUE Stock Holding History

J. Goldman & Co’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-135,000
Closed -$2.12M – 744
2025
Q4 		$2.12M Buy
+135,000
New +$1.82M 0.06% 306

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

J. Goldman & Co's GLUE Position: Q1 2026 in Review

J. Goldman & Co increased its Monte Rosa Therapeutics (GLUE) stake by 432% in Q1 2026, buying an estimated $2.67M and bringing the position to 171,771 shares worth $2.83M. The position accounts for 0.08% of the portfolio, ranked #267.

J. Goldman & Co first reported a position in GLUE in Q4 2025 and has held it in 2 quarters since. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • J. Goldman & Co held 171,771 shares of Monte Rosa Therapeutics worth $2.83M as of Q1 2026.
  • J. Goldman & Co bought 139,480 Monte Rosa Therapeutics shares in Q1 2026, an estimated $2.67M.
  • Monte Rosa Therapeutics made up 0.08% of J. Goldman & Co's portfolio in Q1 2026, its #267 holding.
  • J. Goldman & Co first reported a position in Monte Rosa Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.